BMY 3Q18 results: https://finance.yahoo.com/news/bristol-myers-squibb-reports-third-105900519.html Worldwide Opdivo sales were $1.79B, +42% YoY. Worldwide Eliquis sales were $1.58B, +28% YoY. BMY raised 2018 non-GAAP EPS guidance to $3.80-3.90 (from prior range of $3.55-3.65).